CAMBRIDGE, Mass.--(BUSINESS WIRE)--Javelin Pharmaceuticals (AMEX: JAV) announced today that the Company recently advised the American Stock Exchange (“Amex”) that it has regained compliance with Sections 121A and 802(a) of the Amex Company Guide and is currently in compliance with the Amex Rules regarding director independence.
